Altogether, in our cohort of all collected GIST tumor samples, we saw a similar distribution of mutated genes (KIT, PDGFRA and others) as that reported in the literature (Joensuu et al., 2012; Klug et al., 2022), but, for secondary resistance mutations, we observed a higher number of KIT exon 17 (13 samples) mutations and KIT exon 13 (five samples) mutations, compared to the incidences of these molecular subtypes reported in the literature (Serrano et al., 2019). The gene discussed is PDGFRA; the disease is neoplasm.